Keyword: Bill Ackman

Valeant and Pershing Square are one step closer to putting years of insider trading allegations in the past.

Valeant hit back against eye-device maker Icon in legal fight over proprietary lens technology.

Pfizer spinoff Zoetis met Q2 expectations and brightened its full-year forecast, but it's looking to M&A to drive further growth.

Scott Gottlieb said his FDA would speed generics to market, and that effort boasts an early branded victim: Valeant’s controversial heart med Isuprel.

Valeant Pharmaceuticals has added famed hedge fund manager John Paulson to its board.

Faced with a crippling pile of debt, Valeant on Tuesday slightly increased its 2017 earnings guidance, triggering a 20% run-up in its share price.

Valeant CEO Joe Papa says he's looking at a new, fresh-start name for the scandal-ridden company. We're taking suggestions.

Hedge fund manager Bill Ackman is apologizing to investors for his Valeant mistake—and reflecting on the lessons he’s learned along the way.

Bill Ackman’s Valeant chapter is finally coming to a painful close. The activist investor bailed out of the company, selling his 27.2M shares for just about $11 apiece.

As activist investor William Ackman, a thorn in Zoetis' side for two years, reported that he'd sold off his stake, the animal health giant reported Q4 numbers showing a shaped-up bottom line—the very thing Ackman been pushing for.